Kineta Reports Progress in KVA12123 Cancer Trial
Company Announcements

Kineta Reports Progress in KVA12123 Cancer Trial

Kineta (KA) has shared an update.

Kineta, Inc. has shared exciting news in their latest press release about the progress of their VISTA-101 Phase 1/2 clinical trial. Their innovative immunotherapy treatment, KVA12123, is currently being tested on patients with advanced solid tumors. This update marks a significant milestone for the company and holds potential implications for the future of cancer treatment.

See more data about KA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyKineta transitions from Nasdaq to OTC markets
TheFlyKintara announces Kineta reopens enrollment for VISTA-101 clinical trial
TheFlyKineta reopens enrollment for VISTA-101 clinical trial of KVA12123
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App